The burden of VTE in cancer patients: impacts and novel treatments
Venous thromboembolism (VTE) effects 20% of all cancer patients. In this interview with Cihan Ay, MD, from the Medical University of Vienna, Vienna, Austria, discusses the occurrence and implications ...
Author: VJHemOnc
Added: 06/27/2018 (Source: Oncology Tube)
Source: Oncology Tube - June 27, 2018 Category: Cancer & Oncology Source Type: podcasts
Diagnostic markers to catch thrombosis early in PNH
At the British Society for Haematology (BSH) 2018 Annual Scientific Meeting, held in Liverpool, UK, Anita Hill, MBChB (Hons), MRCP, FRCPath, PhD, from Leeds Teaching Hospital NHS Trust, Leeds, UK, di...
Author: VJHemOnc
Added: 06/26/2018 (Source: Oncology Tube)
Source: Oncology Tube - June 26, 2018 Category: Cancer & Oncology Source Type: podcasts
Thrombosis: a lethal complication in PNH
Thrombosis is the leading cause of morbidity and mortality in paroxysmal nocturnal hemoglobinuria (PNH). In this interview, Anita Hill, MBChB (Hons), MRCP, FRCPath, PhD, from Leeds Teaching Hospital N...
Author: VJHemOnc
Added: 06/26/2018 (Source: Oncology Tube)
Source: Oncology Tube - June 26, 2018 Category: Cancer & Oncology Source Type: podcasts
An Alternative to Dalteparin for Cancer-Related VTE
Dr David Kerr discusses a promising new study suggesting that oral edoxaban may be substituted for daily subcutaneous dalteparin in cancer patients who have had a venous thromboembolism. (Source: Medscape Oncology)
Source: Medscape Oncology - April 2, 2018 Category: Cancer & Oncology Authors: Medscape Source Type: podcasts
Next steps in VTE treatment: will oral edoxoban replace the current standard of care?
There was exciting news at the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA, with data from the Hokusai venous thromboembolism (VTE)-Cancer Study (NCT02073682...
Author: VJHemOnc
Added: 03/12/2018 (Source: Oncology Tube)
Source: Oncology Tube - March 12, 2018 Category: Cancer & Oncology Source Type: podcasts
The Hokusai VTE-Cancer Study: objectives and design
What were the objectives of the Hokusai venous thromboembolism (VTE)-Cancer Study? In this interview, Harry Buller, MD, PhD, of the Academic Medical Centre, Amsterdam, Netherlands, highlights the majo...
Author: VJHemOnc
Added: 03/09/2018 (Source: Oncology Tube)
Source: Oncology Tube - March 9, 2018 Category: Cancer & Oncology Source Type: podcasts
The Hokusai VTE-Cancer Study: the importance of improving VTE treatment
Venous thromboembolism (VTE) remains a major risk for patients with cancer. The current standard of care for VTE includes subcutaneously injecting low-molecular-weight heparin (LMWH), which has shown ...
Author: VJHemOnc
Added: 03/09/2018 (Source: Oncology Tube)
Source: Oncology Tube - March 9, 2018 Category: Cancer & Oncology Source Type: podcasts
Left Atrial Appendage Occlusion for Thromboembolism in Afib, Exposure Therapy for Military PTSD, Hysteroscopic Sterilization, and more
Editor's Summary by Howard Bauchner, MD, Editor in Chief of JAMA, the Journal of the American Medical Association, for the January 23/30, 2018 issue (Source: JAMA: This Week's Audio Commentary)
Source: JAMA: This Week's Audio Commentary - January 23, 2018 Category: General Medicine Authors: JAMA, the Journal of the American Medical Association, and The JAMA Network Source Type: podcasts
Life and Times of Leading Cardiologists: Gilles Montalescot
Magnus Ohman speaks with Gilles Montalescot, whose illustrious career in cardiology and research in thrombosis led him from Paris to Beacon Hill and back. (Source: Medscape Cardiology Podcast)
Source: Medscape Cardiology Podcast - January 18, 2018 Category: Cardiology Authors: Medscape Source Type: podcasts
Potential of next-generation sequencing in the NHS for patients with MPNs
Myeloproliferative Neoplasms (MPNs) carry a risk of complications, such as thrombosis; the degree of risk is influenced in part by genetic factors. In this interview, recorded at the Myeloproliferativ...
Author: VJHemOnc
Added: 12/05/2017 (Source: Oncology Tube)
Source: Oncology Tube - December 5, 2017 Category: Cancer & Oncology Source Type: podcasts
Identifying risk factors for thrombosis in MPNs and treatment strategies
Thrombosis is a major risk factor for early mortality in patients with myeloproliferative neoplasms (MPNs), particularly essential thrombocythemia and polycythemia vera. In this insightful interview, ...
Author: VJHemOnc
Added: 11/24/2017 (Source: Oncology Tube)
Source: Oncology Tube - November 24, 2017 Category: Cancer & Oncology Source Type: podcasts
MPNs and thrombosis: reducing the risk
Patients with myeloproliferative neoplasm (MPNs) are at a higher risk of mortality due to thrombosis compared with unaffected individuals. Speaking from the Myeloproliferative Neoplasms Advances Day 2...
Author: VJHemOnc
Added: 11/17/2017 (Source: Oncology Tube)
Source: Oncology Tube - November 17, 2017 Category: Cancer & Oncology Source Type: podcasts
Fixed daily dose of a low molecular weight heparin compared with an adjusted dose of unfractionated heparin for treating blood clots in the deep veins
Venous thromboembolism is a common and potentially life-threatening condition in which a clot forms in the veins of the leg or pelvis or moves up to the lungs where it blocks a blood vessel. Heparin is one of the treatments and an updated Cochrane Review from February 2017 examines the evidence of its effects. Lindsay Robertson from the Freeman Hospital in Newcastle upon Tyne in the UK tells us about these latest findings. (Source: Podcasts from The Cochrane Library)
Source: Podcasts from The Cochrane Library - June 7, 2017 Category: General Medicine Authors: Cochrane Source Type: podcasts
